OBJECTIVE: Chimerism is well-established for surveillance of acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (HSCT), but interpretation of the results and techniques is not standardized. MATERIALS AND METHODS: We correlated chimerism in 75 AML patients (38 male, 37 female) who underwent myeloablative (n = 36)/reduced (n = 39) allo-HSCT with the risk of relapse and survival. Chimerism was evaluated by quantitative real-time polymerase chain reaction for donor/recipient specific polymorphisms/Y-specific sequences. RESULTS: After HSCT, 40 patients (53%) achieved stable complete donor chimerism (≥ 99.0% of donor alleles), while 35 (47%) failed to achieve stable donor chimerism. Thirty-one patients (41%) showed decreasing donor alleles after having first achieved complete donor chimerism. To investigate the kinetics of mixed chimerism, patients were separated whether they showed subsequent increasing or decreasing donor alleles. Subsequent decrease of donor alleles was associated with relapses in 17 of 18 cases (94%), while no patient with subsequent increasing donor alleles relapsed (p < 0.001). Patients with mixed chimerism and increasing donor alleles had better 2-year disease-free survival (85%) than those with decreasing donor alleles (0%; p < 0.001). CONCLUSIONS: The kinetics of mixed chimerism as assessed by quantitative real-time polymerase chain reaction is an important prognostic predictor in the post-transplantation period of AML patients.
OBJECTIVE: Chimerism is well-established for surveillance of acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (HSCT), but interpretation of the results and techniques is not standardized. MATERIALS AND METHODS: We correlated chimerism in 75 AMLpatients (38 male, 37 female) who underwent myeloablative (n = 36)/reduced (n = 39) allo-HSCT with the risk of relapse and survival. Chimerism was evaluated by quantitative real-time polymerase chain reaction for donor/recipient specific polymorphisms/Y-specific sequences. RESULTS: After HSCT, 40 patients (53%) achieved stable complete donor chimerism (≥ 99.0% of donor alleles), while 35 (47%) failed to achieve stable donor chimerism. Thirty-one patients (41%) showed decreasing donor alleles after having first achieved complete donor chimerism. To investigate the kinetics of mixed chimerism, patients were separated whether they showed subsequent increasing or decreasing donor alleles. Subsequent decrease of donor alleles was associated with relapses in 17 of 18 cases (94%), while no patient with subsequent increasing donor alleles relapsed (p < 0.001). Patients with mixed chimerism and increasing donor alleles had better 2-year disease-free survival (85%) than those with decreasing donor alleles (0%; p < 0.001). CONCLUSIONS: The kinetics of mixed chimerism as assessed by quantitative real-time polymerase chain reaction is an important prognostic predictor in the post-transplantation period of AMLpatients.
Authors: N Jacque; S Nguyen; J-L Golmard; M Uzunov; A Garnier; V Leblond; J-P Vernant; D Bories; N Dhédin Journal: Bone Marrow Transplant Date: 2014-11-10 Impact factor: 5.483
Authors: Hannes Lindahl; Sofie Vonlanthen; Davide Valentini; Andreas T Björklund; Mikael Sundin; Stephan Mielke; Dan Hauzenberger Journal: Bone Marrow Transplant Date: 2022-02-24 Impact factor: 5.174
Authors: Cornelis R van der Torren; Yvette van Hensbergen; Susanne Luther; Zohara Aghai; Zuzana Stachová Rychnavská; Manon Slot; Sicco Scherjon; Nicolaus Kröger; Arnold Ganser; Eva M Weissinger; Els Goulmy; Lothar Hambach Journal: PLoS One Date: 2015-03-16 Impact factor: 3.240
Authors: Tanja Stahl; Caroline Rothe; Manja U Böhme; Aloisa Kohl; Nicolaus Kröger; Boris Fehse Journal: Int J Mol Sci Date: 2016-09-09 Impact factor: 5.923
Authors: Hajnalka Andrikovics; Zoltán Őrfi; Nóra Meggyesi; András Bors; Lívia Varga; Petra Kövy; Zsófia Vilimszky; Fanni Kolics; László Gopcsa; Péter Reményi; Attila Tordai Journal: Int J Mol Sci Date: 2019-09-10 Impact factor: 5.923